CORDIS
EU research results

CORDIS

English EN
iManageCancer - Empowering patients and strengthening self-management in cancer diseases

iManageCancer - Empowering patients and strengthening self-management in cancer diseases

Objective

Chronic cancer treatment places new demands on patients and families to manage their own care. The iManageCancer project will support this challenge and provide a cancer disease self-management platform designed according to the specific needs of patient groups and focusing on the wellbeing of the cancer patient with special emphasis on psycho-emotional evaluation and self-motivated goals. The platform will be centred in a Personal Health Record that will exploit recent advances on Health Avatars for the individual cancer patient surrounded by mHealth applications designed to encourage the patient, enhance clinician-patient communication, maximise compliance to therapy, inform about drug interactions, and contribute to the management of pain and other side-effects of cancer treatment. The Health Avatar PHR will regularly monitor the psycho-emotional status of the patient and will periodically record the everyday life experiences of the cancer patient with respect to the therapy side effects, while different groups of patients and their families will share information through diaries and clinicians are provided with clinical information. The PHR will help assess adherence to therapy, physiological and psychological status while the platform will recommend targeted informative applications and serious games according to the disease type and psycho-emotional status of the patients in order to promote a positive and healthier psycho-emotional state. The disease management platform will be further complemented by an integrated expert system with formal self-management models that will be oriented to decision support, the management of side-effects, adherence to therapy and guidance for patients including drug dose self-adjustments. The iManageCancer platform will be designed on clinical evidence and in close collaboration of clinical experts, IT specialists and patients and will be assessed in clinical pilots with adult and paediatric cancer patients.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Address

Hansastrasse 27c
80686 Munchen

Germany

Activity type

Research Organisations

EU Contribution

€ 952 000

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS

Greece

EU Contribution

€ 747 500

UNIVERSITAT DES SAARLANDES

Germany

EU Contribution

€ 374 500

PHILIPS ELECTRONICS NEDERLAND B.V.

Netherlands

EU Contribution

€ 349 637

CANCER INTELLIGENCE LIMITED

United Kingdom

EU Contribution

€ 445 000

UNIVERSITY OF BEDFORDSHIRE

United Kingdom

EU Contribution

€ 603 750

ISTITUTO EUROPEO DI ONCOLOGIA SRL

Italy

EU Contribution

€ 464 150

PROMOTION SOFTWARE GMBH

Germany

EU Contribution

€ 466 250

SERIOUS GAMES SOLUTIONS GMBH

Germany

PHILIPS ELECTRONICS UK LIMITED

United Kingdom

EU Contribution

€ 349 637

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 103 750

Project information

Grant agreement ID: 643529

Status

Closed project

  • Start date

    1 February 2015

  • End date

    31 July 2018

Funded under:

H2020-EU.3.1.4.

  • Overall budget:

    € 4 856 174

  • EU contribution

    € 4 856 174

Coordinated by:

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

This project is featured in...